Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Prognostic value of MRD in elderly patients with secondary AML

Paola Minetto • 9 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes CPX-351 Fludarabine

Paola Minetto, MD, IRCCS Ospedale Policlinico San Martino, Genova, Italy, discusses the prognostic impact of measurable residual disease (MRD) assessment in elderly patients with secondary acute myeloid leukemia (AML) who receive induction therapy with either a fludarabine-containing regimen or CPX-351. Data from 136 elderly patients with secondary AML was analyzed. Dr Minetto reports that MRD demonstrated a significant prognostic value in terms of overall survival in all treatment groups and could help to identify elderly AML patients with a suboptimal response to treatment. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Paola Minetto

1:25
Harnessing NK-cells to treat AML
Paola Minetto • 9 Dec 2023
1:50
Preliminary results of tagraxofusp in R/R CD123-positive AML: GIMEMA AML2020
Paola Minetto • 9 Dec 2023
1:22
Centralized MRD assessment in patients with AML treated with venetoclax + FLAI: GIMEMA AML1718 trial
Paola Minetto • 9 Dec 2023

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals